Clinical trial · Observational
The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study
Prevalence and Prognostic Impact of Epigenetic MMRd in Endometrial Carcinomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In recent years, the incidence of endometrial carcinoma (EC) has increased significantly and patients tends to be younger. In addition to known risk factors such as obesity, hypertension and diabetes, genetic factors also play an important role in the occurrence and development of EC. Among them, Mismatch Repair Defect (MMR) can produce mutant phenotypes, leading to cancer susceptibility. Although some articles indicated that epigenetic MMRd, one type of MMRd, predicted poor prognosis among endometrial carcinoma patients, hitherto, the clinicopathological significance and prognosis of epigenetic MMRd has not been determined. To date, there are no relevant large-sample data to investigate the prevalence of epigenetic MMRd in Chinese population, as well as the impact on the prognosis of endometrial cancer. In this setting, The purpose of this study was to investigate the prevalence of epigenetic MMRd and its impact on clinicopathology and prognosis on endometrial cancer among Chinese patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Neoplasms | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- epigenetic MMR deficiency
- description
- Tumors with MMR abnormalities by IHC and MLH1 methylation
- label
- probable MMR mutations
- description
- Tumors with MMR abnormalities by IHC and without MLH1 methylation
- label
- MMR proficient
- description
- without MMR abnormalities by IHC
Primary outcomes (1)
- measure
- Proportion of MMRd caused by MLH1 promoter methylation in endometrial carcinoma
- timeFrame
- up to two years
- description
- the prevalence of epigenetic MMRd in endometrial cancer
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * all patients diagnosed with endometrial cancer in our hospital from 2019 to 2022 Exclusion Criteria: * those without histological specimens in our hospital
References
Publications (0)
Data not yet available